Other Articles
- Vestaron Corporation Hires New President and CEO [Tuesday 06 September 2011, 23:11]
- Vestaron Corporation Receives FNIH Grant for Malaria Control Research [Thursday 25 August 2011, 23:11]
- FNIH Awards Nearly $6 Million in Grants for Malaria Control Research [Thursday 25 August 2011, 21:09]
- Vestaron Corporation Announces New Leadership [Thursday 28 April 2011, 18:06]
- Scientific Research Fund Open Prairie Ventures Opens Office in Downtown Kalamazoo [Monday 14 March 2011, 05:05]
Robert M. Kennedy Joins Venomix as Vice President Research
Written by Administrator
Thursday, 29 January 2009 07:02
KALAMAZOO, Mich., January 20, 2009 – Venomix, Inc. is pleased to announce that Robert M. Kennedy, Ph.D., has joined the company as vice president of research. Kennedy was previously a director of International Discovery Sourcing Consultants, LLC, of Ann Arbor, Mich. He is also founder of Metabalog, LLC, of Ann Arbor.
“We are delighted that Bob has joined Venomix,” said John L. McIntyre, Ph.D., president and chief operating officer of Venomix. “He has a broad background in developing new chemical entities – just what we need to bring our spider venom peptides to market as commercial insecticides.”
Kennedy has a strong background in both academic and industrial research. With Pfizer Global Research and Development in Ann Arbor he directed a number of groups including Cardiovascular Chemistry, PET Chemistry and Combinatorial Chemistry. He also held research positions at Parke-Davis and American Cyanamid. Under his leadership at Pfizer/Parke-Davis, nine drug candidates were identified with five progressing to clinical trials, including a follow-on candidate to Lipitor. Kennedy received his doctorate in organic chemistry from Virginia Polytechnic and State University. Upon completing a postdoctoral fellowship at the Massachusetts Institute of Technology, he became an assistant professor at Columbia University.
Venomix is developing a new generation of insecticides using peptides from spiders. The company’s technology is based on ground-breaking research conducted at the University of
Connecticut. Over 50 unique, spider-venom peptides have been identified. This patented technology is exclusively licensed to Venomix. Products under development have a unique mode of action, are highly effective against insects and related pests and are harmless to non-target species, including humans. Target markets include agriculture, animal health and specialty non-crop uses such as household insects. Venomix products will be ideally suited for the environmentally conscious twenty-first century. www.venomix.net
# # #
| < Prev | Next > |
|---|